HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Incremental utility of expanded mutation panel when used in combination with microRNA classification in indeterminate thyroid nodules.

AbstractINTRODUCTION:
Focused and expanded mutation panels were assessed for the incremental utility of using an expanded panel in combination with microRNA risk classification.
METHODS:
Molecular results were reviewed for patients who underwent either a focused mutation panel (ThyGenX®) or an expanded mutation panel (ThyGeNEXT®) for strong and weak oncogenic driver mutations and fusions. microRNA results (ThyraMIR®) predictive of malignancy, including strong positive results highly specific for malignancy, were examined.
RESULTS:
Results of 12 993 consecutive patients were reviewed (focused panel = 8619, expanded panel = 4374). The expanded panel increased detection of strong drivers by 8% (P < .001), with BRAFV600E and TERT promoters being the most common. Strong drivers were highly correlated with positive microRNA results of which 90% were strongly positive. The expanded panel increased detection of coexisting drivers by 4% (P < .001), with TERT being the most common partner often paired with RAS. It increased the detection of weak drivers, with RAS and GNAS being the most common. 49% of nodules with weak drivers had positive microRNA results of which 33% were strongly positive. The expanded panel also decreased the number of nodules lacking mutations and fusions by 15% (P < .001), with 8% of nodules having positive microRNA results of which 22% were strongly positive.
CONCLUSIONS:
Using expanded mutation panels that include less common mutations and fusions can offer increased utility when used in combination with microRNA classification, which helps to identify high risk of malignancy in the cases where risk is otherwise uncertain due to the presence of only weak drivers or the absence of all drivers.
AuthorsSara Jackson, Gyanendra Kumar, Anna B Banizs, Nicole Toney, Jan F Silverman, Christina M Narick, Sydney D Finkelstein
JournalDiagnostic cytopathology (Diagn Cytopathol) Vol. 48 Issue 1 Pg. 43-52 (Jan 2020) ISSN: 1097-0339 [Electronic] United States
PMID31675178 (Publication Type: Journal Article)
Copyright© 2019 The Authors. Diagnostic Cytopathology published by Wiley Periodicals, Inc.
Chemical References
  • MicroRNAs
  • BRAF protein, human
  • Proto-Oncogene Proteins B-raf
  • TERT protein, human
  • Telomerase
Topics
  • Biopsy, Fine-Needle (methods)
  • Female
  • Humans
  • Male
  • MicroRNAs (genetics)
  • Middle Aged
  • Molecular Diagnostic Techniques
  • Proto-Oncogene Proteins B-raf (genetics)
  • Telomerase (genetics)
  • Thyroid Neoplasms (diagnosis, genetics, pathology)
  • Thyroid Nodule (genetics, pathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: